# CDT Equity Inc. (CDTTW) — delisting/voluntary [completed]
Source: SEC API (secapi.ai) · situation sit_36a1f26787eb5dda3446 · retrieved 2026-08-11T16:13:21.788Z

## Overview
CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.) is a pharmaceutical company that develops and commercializes pharmaceutical preparations.

CDT Equity Inc. entered into an Amended and Restated Loan Agreement and Amended and Restated Senior Secured Convertible Note with J.J. Astor & Co. on June 30, 2026. The original note was issued on June 11, 2026 with a principal amount of $1,971,000 (representing a 1.35x factor on the $1,460,000 loan). The company receives $1,460,000 in net proceeds funded in two tranches: the first tranche of $268,299.70 was funded on June 11, 2026 to pay Delaware franchise taxes, and the second tranche of $1,133,300.30 was funded on June 30, 2026. The amended note requires twenty-four equal weekly installment payments of $82,125 commencing on July 10, 2026 and continuing each Friday thereafter through December 18, 2026 (the maturity date). The note is senior secured, convertible at the lender's option at a conversion price equal to the greater of 90% of the lowest 10-day VWAP or the applicable Nasdaq floor price, subject to a 19.99% maximum conversion share limitation. Upon an event of default, the outstanding principal increases to 120% and accrues interest at 19% per annum, with conversion at 70% of the lowest 20-day VWAP or the floor price.

## Terms
- Counterparty: J.J. Astor & Co. · Deal value: $1.5M · Consideration: mixed

## Key dates
- Expiry 2026-12-18 · Expected close 2026-06-30 · Completed 2026-07-07

## Timeline
- 2026-07-07 · 8-K (0001493152-26-032375): 8-K - CDT Equity Inc. — *CDT Equity Inc. (formerly Conduit Pharmaceuticals Inc.) is a pharmaceutical company that develops and commercializes pharmaceutical preparations.* CDT Equity Inc. entered into an Amended and Restated Loan Agreement and Amended and Restated Senior Secured Convertible Note with J.J. Astor & Co. on June 30, 2026. The original note was issued on June 11, 2026 with a principal amount of $1,971,000 (representing a 1.35x factor on the $1,460,000 loan). The company receives $1,460,000 in net proceeds funded in two tranches: the first tranche of $268,299.70 was funded on June 11, 2026 to pay Delaware franchise taxes, and the second tranche of $1,133,300.30 was funded on June 30, 2026. The amended note requires twenty-four equal weekly installment payments of $82,125 commencing on July 10, 2026 and continuing each Friday thereafter through December 18, 2026 (the maturity date). The note is senior secured, convertible at the lender's option at a conversion price equal to the greater of 90% of the lowest 10-day VWAP or the applicable Nasdaq floor price, subject to a 19.99% maximum conversion share limitation. Upon an event of default, the outstanding principal increases to 120% and accrues interest at 19% per annum, with conversion at 70% of the lowest 20-day VWAP or the floor price.
  https://www.sec.gov/Archives/edgar/data/1896212/0001493152-26-032375.txt

## Citations
- 0001493152-26-032375 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226032375